Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Farmers Insurance
Accenture
Mallinckrodt
Teva
McKesson
US Army
Boehringer Ingelheim

Generated: October 20, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYDRALAZINE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for hydralazine hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00000499 Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study) Completed National Institute on Aging (NIA) Phase 2 The SHEP Pilot Study had six objectives, each designed to develop and test critical components of a full scale trial directed at the health consequences of treating isolated systolic hypertension (ISH) in the elderly. l. To estimate and compare the yield of participants for randomization into a clinical trial from various community groups using various recruitment techniques. 2. To estimate compliance with the visit schedule and to the prescribed double-blind regimens. 3. To estimate and compare the effectiveness of specified antihypertensive medications in reducing the blood pressure. 4. To estimate and compare the unwanted effects of specified antihypertensive medication in an elderly population. 5. To evaluate the feasibility and effectiveness of periodic behavioral assessment in this population. 6. To develop and test methods of ascertaining stroke and other disease endpoints.
NCT00000499 Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 The SHEP Pilot Study had six objectives, each designed to develop and test critical components of a full scale trial directed at the health consequences of treating isolated systolic hypertension (ISH) in the elderly. l. To estimate and compare the yield of participants for randomization into a clinical trial from various community groups using various recruitment techniques. 2. To estimate compliance with the visit schedule and to the prescribed double-blind regimens. 3. To estimate and compare the effectiveness of specified antihypertensive medications in reducing the blood pressure. 4. To estimate and compare the unwanted effects of specified antihypertensive medication in an elderly population. 5. To evaluate the feasibility and effectiveness of periodic behavioral assessment in this population. 6. To develop and test methods of ascertaining stroke and other disease endpoints.
NCT00000620 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed Centers for Disease Control and Prevention Phase 3 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed National Eye Institute (NEI) Phase 3 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 3 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for hydralazine hydrochloride

Condition Name

Condition Name for hydralazine hydrochloride
Intervention Trials
Hypertension 10
Heart Failure 6
Postoperative Pain 2
Cervical Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for hydralazine hydrochloride
Intervention Trials
Hypertension 14
Heart Failure 10
Pre-Eclampsia 8
Eclampsia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for hydralazine hydrochloride

Trials by Country

Trials by Country for hydralazine hydrochloride
Location Trials
United States 55
Mexico 6
Canada 3
Egypt 2
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for hydralazine hydrochloride
Location Trials
Tennessee 6
New York 6
Ohio 4
Pennsylvania 3
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for hydralazine hydrochloride

Clinical Trial Phase

Clinical Trial Phase for hydralazine hydrochloride
Clinical Trial Phase Trials
Phase 4 13
Phase 3 11
Phase 2/Phase 3 2
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for hydralazine hydrochloride
Clinical Trial Phase Trials
Completed 19
Recruiting 10
Unknown status 7
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for hydralazine hydrochloride

Sponsor Name

Sponsor Name for hydralazine hydrochloride
Sponsor Trials
National Institute of Cancerología 6
Psicofarma S.A. de C.V. 5
National Council of Science and Technology, Mexico 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for hydralazine hydrochloride
Sponsor Trials
Other 77
NIH 8
Industry 6
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Johnson and Johnson
Express Scripts
Accenture
McKinsey
Cipla
Merck
Teva
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.